RT Journal Article SR Electronic T1 Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5803 OP 5809 DO 10.21873/anticanres.13784 VO 39 IS 10 A1 SHOTARO YASUOKA A1 TAKESHI YUASA A1 MASAHIRO OGAWA A1 YOSHINOBU KOMAI A1 NOBORU NUMAO A1 SHINYA YAMAMOTO A1 YUKIHIRO KONDO A1 JUNJI YONESE YR 2019 UL http://ar.iiarjournals.org/content/39/10/5803.abstract AB Background/Aim: Cabazitaxel (CBZ) is approved for docetaxel-resistant castration-resistant prostate cancer (CRPC). This retrospective study aimed at assessing the efficacy and prognostic markers of cabazitaxel treatment in Japanese CRPC patients. Patients and Methods: The medical records of 44 consecutive Japanese patients with CRPC who started cabazitaxel at our Institution between January 2011 and February 2019 were reviewed and statistically analysed. Results: The median follow-up period after cabazitaxel initiation was 13.2 [interquartile range (IQR)=6.9-21.5] months. The objective response rate, median progression-free survival period, and median overall survival period (OS) were 45.5%, 4.3 months, and 20.7 months, respectively. On multivariate analysis, higher prostate-specific antigen (PSA; >100 ng/ml), lower haemoglobin (<10 g/dl), and lower number of prior docetaxel therapy cycles (<10) were predictors for shorter OS. Conclusion: Patients with anemia, high PSA, and lower number of docetaxel therapy cycles might have shorter survival period from introduction of cabazitaxel therapy. In addition, PSA decline might still be a useful indicator as a predictor of prognosis of the metastatic CRPC patients treated with cabazitaxel.